{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:26:16Z","timestamp":1779269176340,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":365,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Drug interactions with immunosuppressive drugs are a major problem associated with protease inhibitor\u2013based antiviral triple therapy for hepatitis C virus (HCV) reinfection after liver transplantation. In this retrospective cohort study, we analyzed biomarkers of the immunosuppressive effects of cyclosporine A (CSA) by quantifying nuclear factor of activated T cells (NFAT)\u2013regulated gene expression during telaprevir (TVR) therapy in 5 liver transplant patients. Furthermore, dose adjustments and blood concentrations of CSA as well as the clinical course were analyzed. We observed a clear impact of TVR not only on doses and blood concentrations but also on the immunosuppressive effects of CSA. Despite apparently adequate CSA trough concentrations, the CSA peak concentration decreased to 68% (range = 44%-90%). This was associated with a 1.9-fold (1.6- to 4.1-fold) increase in the residual gene activity of NFAT-regulated genes, which indicated reduced immunosuppressive activity of CSA with TVR co-medication. The median dose of CSA was reduced to 25% (range = 16%-48%) and 31% (range = 22%-64%) after 1 and 2 weeks, respectively. The CSA drug clearance was reduced to 38.7% (range = 31.0%-49.4%). We report excellent antiviral efficacy. At the end of the observation period, all patients were HCV RNA\u2013negative (1 patient at 18 weeks, 1 patient at 12 weeks, and 3 patients at 4 weeks after the end of therapy). Safety was acceptable, with mild acute rejection and reactivation of cytomegalovirus being the most serious adverse events. One patient with histologically proven recurrent cholestatic hepatitis before therapy underwent retransplantation during the course of antiviral therapy. In conclusion, the immunomonitoring of NFAT-regulated gene expression indicated reduced immunosuppressive activity of CSA during antiviral therapy with TVR in our cohort of liver transplant patients. Thus, the immunosuppressive effects of CSA may be overestimated if one is looking only at trough concentrations during co-medication with protease inhibitors or other strong cytochrome P450 3A inhibitors. Immunomonitoring of NFAT-regulated gene expression could, therefore, help to prevent overimmunosuppression or underimmunosuppression. <jats:italic toggle=\"yes\">Liver Transpl 20:1106\u20131117, 2014<\/jats:italic>. \u00a9 2014 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23925","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T09:32:31Z","timestamp":1401787951000},"page":"1106-1117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy"],"prefix":"10.1097","volume":"20","author":[{"given":"Katja","family":"Roos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Giese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Eisenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20250124","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation.","volume":"35","author":"GarciaRetortillo","year":"2002","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R6-13-20250124","first-page":"209A","article-title":"Twicedaily telaprevir in combination with peginterferon alfa2aribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter REFRESH study abstract.","volume":"58","author":"Brown","year":"2013","journal-title":"Hepatology"},{"key":"R7-13-20250124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0033-1356345","article-title":"Treatment of recurrent genotype 1 hepatitis C postliver transplantation: single center experience with telaprevirbased triple therapy.","volume":"52","author":"Werner","year":"2014","journal-title":"Z Gastroenterol"},{"key":"R8-13-20250124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.","volume":"60","author":"Coilly","year":"2014","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"R9-13-20250124","first-page":"429A","article-title":"Higher sustained virologic response (SVR12) achievable in liver transplant (LT) recipients with hepatitis C (HCV) treated with protease inhibitor (PI) triple therapy (TT) abstract.","volume":"58","author":"Stravitz","year":"2013","journal-title":"Hepatology"},{"key":"R11-13-20250124","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","article-title":"Human Pglycoprotein transports cyclosporin A and FK506.","volume":"268","author":"Saeki","year":"1993","journal-title":"J Biol Chem"},{"key":"R12-13-20250124","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R13-13-20250124","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12062","article-title":"Current management and perspectives for HCV recurrence after liver transplantation.","volume":"33","author":"Coilly","year":"2013","journal-title":"Liver Int"},{"issue":"suppl 1","key":"R14-13-20250124","first-page":"1043A","article-title":"Twicedaily telaprevir in combination with peginterferon alfa2aribavirin in genotype 1 HCV liver transplant recipients: interim week 16 calcineurin inhibitor, telaprevir, and ribavirin pharmacokinetics from the prospective multicenter REFRESH study abstract.","volume":"46","author":"Fontana","year":"2013","journal-title":"Hepatology"},{"key":"R15-13-20250124","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/lt.20165","article-title":"Management of drugtodrug interactions between cyclosporine A and the proteaseinhibitor lopinavirritonavir in livertransplanted HIVinfected patients.","volume":"10","author":"Vogel","year":"2004","journal-title":"Liver Transpl"},{"issue":"suppl","key":"R16-13-20250124","doi-asserted-by":"crossref","first-page":"420S","DOI":"10.1016\/j.transproceed.2004.01.054","article-title":"Evolution of the therapeutic drug monitoring of cyclosporine.","volume":"36","author":"Citterio","year":"2004","journal-title":"Transplant Proc"},{"key":"R17-13-20250124","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1016\/j.transproceed.2007.06.075","article-title":"Efficacy of C0 and C2 monitoring in adult liver transplant recipients treated with neoral, mycophenolate mofetil, and steroids.","volume":"39","author":"Treckmann","year":"2007","journal-title":"Transplant Proc"},{"key":"R18-13-20250124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704374","article-title":"Increased incidence of acute graftversushost disease with the continuous infusion of cyclosporine A compared to twicedaily infusion.","volume":"33","author":"Ogawa","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R19-13-20250124","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.21087","article-title":"Decreased incidence of acute graftversushost disease by continuous infusion of cyclosporine with a higher target blood level.","volume":"83","author":"Oshima","year":"2008","journal-title":"Am J Hematol"},{"key":"R20-13-20250124","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.TP.0000109260.00094.01","article-title":"Monitoring of NFATregulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A.","volume":"77","author":"Giese","year":"2004","journal-title":"Transplantation"},{"key":"R21-13-20250124","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FTD.0b013e318226dac7","article-title":"Pharmacodynamic disparities in tacrolimustreated patients developing cytomegalus virus viremia.","volume":"33","author":"Sommerer","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R22-13-20250124","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/lt.22254","article-title":"Immunomonitoring of nuclear factor of activated T cellsregulated gene expression: the first clinical trial in liver allograft recipients.","volume":"17","author":"Zahn","year":"2011","journal-title":"Liver Transpl"},{"key":"R23-13-20250124","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clim.2009.03.520","article-title":"Monitoring immunosuppression with measures of NFAT decreases cancer incidence.","volume":"132","author":"Giese","year":"2009","journal-title":"Clin Immunol"},{"issue":"suppl 1","key":"R24-13-20250124","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0168-8278(13)60800-4","article-title":"Efficacy of telaprevir dosed twice daily versus every 8 hours by IL28B genotype: results from the phase III OPTIMIZE study abstract.","volume":"58","author":"Buti","year":"2013","journal-title":"J Hepatol"},{"key":"R25-13-20250124","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.23542","article-title":"Telaprevirbased triple therapy in liver transplant patients with hepatitis C virus: a 12week pilot study providing safety and efficacy data.","volume":"18","author":"Werner","year":"2012","journal-title":"Liver Transpl"},{"key":"R26-13-20250124","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/jps.2600720843","article-title":"Computation of modelindependent pharmacokinetic parameters during multiple dosing.","volume":"72","author":"Bauer","year":"1983","journal-title":"J Pharm Sci"},{"key":"R27-13-20250124","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cca.2011.09.041","article-title":"Calcineurin inhibitors and NFATregulated gene expression.","volume":"413","author":"Sommerer","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R28-13-20250124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/FTD.0b013e318210e6d0","article-title":"Monitoring of nuclear factor of activated Tcellregulated gene expression in de novo and longterm liver transplant recipients treated with cyclosporine A.","volume":"33","author":"Herden","year":"2011","journal-title":"Ther Drug Monit"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23925","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201409000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:34:24Z","timestamp":1737740064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201409000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23925","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}